Epithalon

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG). It was developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia as a synthetic version of Epithalamin, a peptide extract derived from the pineal gland. Khavinson's research on peptide bioregulators spans over 40 years and has been a significant focus of Russian anti-aging research.

The primary mechanism of interest for Epithalon is its reported ability to activate telomerase, the enzyme responsible for adding protective telomere sequences to the ends of chromosomes. Telomeres shorten with each cell division and are considered a biomarker of biological aging. When telomeres become critically short, cells enter senescence or die. By activating telomerase, Epithalon may theoretically help maintain telomere length and extend the replicative capacity of cells.

Studies from Khavinson's laboratory have reported that Epithalon can increase telomerase activity in human somatic cells, elongate telomeres, and extend the lifespan of cells in culture. Animal studies, primarily in mice and rats, showed that Epithalon treatment was associated with increased maximum lifespan. Research in aged non-human subjects demonstrated restoration of melatonin production and normalization of circadian rhythms, suggesting a regulatory effect on pineal gland function.

It is important to note that the majority of published research on Epithalon originates from a single research group, and large-scale independent replication studies are limited. While the theoretical basis — telomerase activation for anti-aging — is scientifically compelling, the clinical evidence base does not yet meet the standards typically required for therapeutic claims. The peptide has gained a significant following in the anti-aging community based on the published research and the broader scientific interest in telomere biology.